Real World Prostate Cancer Registry
Recruiting · NCT06355336 · Observational (researchers observe without assigning treatment) · Lead sponsor: Cincinnati Cancer Advisors
View the official record on ClinicalTrials.gov →What this trial is about
Prostate cancer is the most common cancer diagnosed in men in the USA with 268,490 cases diagnosed in 2022 constituting 27% of male cancers and 34,500 deaths (11%) occurred in same year.1 Prostate cancer is a very heterogeneous disease that has different presentations, molecular and pathological features, stages, and disease biology. The treatment options are dependent on the disease stage, its features, and the patient's condition and preferences. The disease outcome also varies significantly due to the previous heterogeneity of the features in addition to other social determinants of health. Therefore, it is critical to obtain real-world data that reflects the actual patterns of prostate cancer presentation, work up, management, and outcome. Real World Prostate Cancer Registry (RWPCR) aims at compiling real world data from patients presented with prostate cancer in the tristate area. The data collection will be prospective and longitudinal including patients' demographics and disease characteristics, work up, management, and outcome.
Who can take part
Inclusion criteria
- All patients with pathologically confirmed primary prostate cancer
- Diagnosis since January 1st, 2023
- Acceptance to sign the consent form
- years old or older
- Resident of Ohio, Kentucky or Indiana
Exclusion criteria
- Having diagnosis of other cancer except squamous cell cancer of the skin
- Refusal to sign a consent form.
Where it is running
1 location listed across 1 US state.
- Cincinnati Cancer Advisors - Cincinnati, Ohio, United States